The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review
Open accessAbstract
Newer antipsychotics introduced in clinical practice in recent years include clozapine, risperidone, olanzapine, quetiapine, sertindole, ziprasidone, aripiprazole and amisulpride. These agents are subject to drug–drug interactions with other psychotropic agents or with medications used in the treatment of concomitant physical illnesses. Most pharmacokinetic interactions with newer antipsychotics occur at the metabolic level and usually involve changes in the activity of the major drug‐metabolizing enzymes involved in their biotransformation, i.e. the cytochrome P450 (CYP) monooxygenases and/or uridine diphosphate‐glucuronosyltransferases (UGT). Clozapine is metabolized primarily by CYP1A2, with additional contribution by other CYP isoforms. Risperidone is metabolized primarily by CYP2D6 and, to a lesser extent, CYP3A4. Olanzapine undergoes both direct conjugation and CYP1A2‐mediated oxidation. Quetiapine is metabolized by CYP3A4, while sertindole and aripiprazole are metabolized by CYP2D6 and CYP3A4. Ziprasidone pathways include aldehyde oxidase‐mediated reduction and CYP3A4‐mediated oxidation. Amisulpride is primarily excreted in the urine and undergoes relatively little metabolism. While novel antipsychotics are unlikely to interfere with the elimination of other drugs, co‐administration of inhibitors or inducers of the major enzymes responsible for their metabolism may modify their plasma concentrations, leading to potentially significant effects. Most documented metabolic interactions involve antidepressant and anti‐epileptic drugs. Of a particular clinical significance is the interaction between fluvoxamine, a potent CYP1A2 inhibitor, and clozapine. Differences in the interaction potential among the novel antipsychotics currently available may be predicted based on their metabolic pathways. The clinical relevance of these interactions should be interpreted in relation to the relative width of their therapeutic index. Avoidance of unnecessary polypharmacy, knowledge of the interaction profiles of individual agents, and careful individualization of dosage based on close evaluation of clinical response and, possibly, plasma drug concentrations are essential to prevent and minimize potentially adverse drug interactions in patients receiving newer antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., Gigleux, S. F., Green, M., Hum, D. W., Iyanagi, T., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199708000-00001 · Cited by 1,183
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Drug Interactions with Tobacco Smoking: An Update
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 692
Olanzapine: Pharmacokinetic and Pharmacodynamic Profile
Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., & Beasley, C. M. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937030-00001 · Cited by 544
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Clinical Pharmacokinetics of Quetiapine: An Atypical Antipsychotic
DeVane, C. L., & Nemeroff, C. B. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00003 · Cited by 386
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Cited by
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Chemical Aspects of Human and Environmental Overload with Fluorine
Han, J., Kiss, L., Mei, H., Remete, A. M., Ponikvar-Svet, M., Sedgwick, D. M., Roman, R., Fustero, S., Moriwaki, H., & Soloshonok, V. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01263 · Cited by 537
Schizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Spina, E., Santoro, V., & D'Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 361
Self-citation
Metadata
- Authors
- Spina, E., & De Leon, J.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2006-12-22
- Volume
- 100
- Issue
- 1
- Pages
- 4-22
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2096739998
- Cited by
- 271
- References
- 155
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. https://app.cochat.ai/papers/10.1111/j.1742-7843.2007.00017.x
- The paper
- Spina, E., & De Leon, J. (2007). Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2007.00017.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.